Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores.

Braithwaite RS, Fridsma D, Roberts MS.

Med Decis Making. 2006 Mar-Apr;26(2):182-93.

PMID:
16525172
2.

Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax.

Fowler RA, Sanders GD, Bravata DM, Nouri B, Gastwirth JM, Peterson D, Broker AG, Garber AM, Owens DK.

Ann Intern Med. 2005 Apr 19;142(8):601-10.

PMID:
15838066
3.

Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination.

Schmitt B, Dobrez D, Parada JP, Kyriacou DN, Golub RM, Sharma R, Bennett C.

Arch Intern Med. 2007 Apr 9;167(7):655-62.

PMID:
17420423
4.

An ounce of prevention is worth a pound of cure: improving communication to reduce mortality during bioterrorism responses.

Brandeau ML, Zaric GS, Freiesleben J, Edwards FL, Bravata DM.

Am J Disaster Med. 2008 Mar-Apr;3(2):65-78.

PMID:
18522248
5.

Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.

Kyriacou DN, Dobrez D, Parada JP, Steinberg JM, Kahn A, Bennett CL, Schmitt BP.

Biosecur Bioterror. 2012 Sep;10(3):264-79. Epub 2012 Jul 30.

6.

No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001.

Baggett HC, Rhodes JC, Fridkin SK, Quinn CP, Hageman JC, Friedman CR, Dykewicz CA, Semenova VA, Romero-Steiner S, Elie CM, Jernigan JA.

Clin Infect Dis. 2005 Oct 1;41(7):991-7. Epub 2005 Aug 29.

PMID:
16142664
7.

Modeling the logistics of response to anthrax bioterrorism.

Zaric GS, Bravata DM, Cleophas Holty JE, McDonald KM, Owens DK, Brandeau ML.

Med Decis Making. 2008 May-Jun;28(3):332-50. doi: 10.1177/0272989X07312721. Epub 2008 Mar 18.

PMID:
18349432
8.

The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.

Doolan DL, Freilich DA, Brice GT, Burgess TH, Berzins MP, Bull RL, Graber NL, Dabbs JL, Shatney LL, Blazes DL, Bebris LM, Malone MF, Eisold JF, Mateczun AJ, Martin GJ.

J Infect Dis. 2007 Jan 15;195(2):174-84. Epub 2006 Dec 6.

PMID:
17191162
9.

Increased US prescription trends associated with the CDC Bacillus anthracis antimicrobial postexposure prophylaxis campaign.

Shaffer D, Armstrong G, Higgins K, Honig P, Coyne P, Boxwell D, Beitz J, Leissa B, Murphy D.

Pharmacoepidemiol Drug Saf. 2003 Apr-May;12(3):177-82.

PMID:
12733470
10.

Simulation modeling of anthrax spore dispersion in a bioterrorism incident.

Reshetin VP, Regens JL.

Risk Anal. 2003 Dec;23(6):1135-45.

PMID:
14641889
11.

Responding to the threat of bioterrorism: a microbial ecology perspective--the case of anthrax.

Atlas RM.

Int Microbiol. 2002 Dec;5(4):161-7. Epub 2002 Aug 20. Review.

12.

Learning from the 2001 anthrax attacks: immunological characteristics.

Hadler JL.

J Infect Dis. 2007 Jan 15;195(2):163-4. Epub 2006 Dec 6. No abstract available.

PMID:
17191158
13.

Interim guidelines for investigation of and response to Bacillus anthracis exposures.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2001 Nov 9;50(44):987-90.

14.

Inhalational anthrax.

Cuneo BM.

Respir Care Clin N Am. 2004 Mar;10(1):75-82. Review.

PMID:
15062228
15.

[Inhalation anthrax].

Hansen TH.

Ugeskr Laeger. 2000 Sep 4;162(36):4786-9. Review. Danish.

PMID:
10994373
16.

Bacillus anthracis contamination and inhalational anthrax in a mail processing and distribution center.

Sanderson WT, Stoddard RR, Echt AS, Piacitelli CA, Kim D, Horan J, Davies MM, McCleery RE, Muller P, Schnorr TM, Ward EM, Hales TR.

J Appl Microbiol. 2004;96(5):1048-56.

17.

Summaries for patients. What is the most cost-effective way to protect people in the event of an anthrax terror attack?

[No authors listed]

Ann Intern Med. 2005 Apr 19;142(8):I40. No abstract available.

PMID:
15838060
18.

Occupational health guidelines for remediation workers at Bacillus anthracis-contaminated sites--United States, 2001-2002.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2002 Sep 6;51(35):786-9.

19.

Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2002 Nov 15;51(45):1024-6.

20.

Pulmonary deposition of aerosolized Bacillus atrophaeus in a Swine model due to exposure from a simulated anthrax letter incident.

Duncan EJ, Kournikakis B, Ho J, Hill I.

Inhal Toxicol. 2009 Feb;21(2):141-52. doi: 10.1080/08958370802412629 .

PMID:
18923948

Supplemental Content

Support Center